Guillermo Sotomayor‐Duque
ORCID: 0000-0002-2935-5265
· 1 paper in corpus
BackgroundAllogeneic stem cell transplantation (ASCT) represents the only option with a potential cure rate of 30% to 50% in myelodysplastic syndrome (MDS); however, < 5% of patients are optimal candidates for this management. Therapeutic o…